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SecretionThe endoplasmic reticulum chaperone GRP94 is essential for early embryonic development and in particular
affects differentiation of muscle lineages. To determine why an ubiquitously expressed protein has such a
speciﬁc effect, we investigated the function of GRP94 in the differentiation of established myogenic cell lines
in culture. Using both genetic suppression of expression, via RNA interference, and inhibition of function, via
speciﬁc chemical inhibitors, we show that GRP94 expression and activity are needed for the in vitro fusion of
myoblasts precursors into myotubes and the expression of contractile proteins that mark terminal
differentiation. The inhibition can be complemented by addition of insulin-like growth factors to the
cultures. GRP94 is not needed for the initial steps of myogenesis, only for the steps downstream of MyoD up-
regulation, coinciding with the known need for synergistic input from growth factor signaling. Indeed,
GRP94 is needed for the production of insulin-like growth factors I and II (IGF-I and IGF-II) by the
differentiating cells. Moreover, the depletion of the chaperone does not increase the rate of apoptosis that
always accompanies myogenic differentiation. Thus, the major effect of GRP94 on muscle differentiation is
mediated by its regulation of IGF production.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
A number of lines of evidence point to an important role for the ER
chaperone GRP94 in muscle physiology. First, grp94−/− ES cells
cannot differentiate into any of the muscle sub-lineages [1] and
reduction of GRP94 levels in skeletal myoblasts leads to loss of
myocyte fusion competence [2]. Second, GRP94 expression is up-
regulated during prenatal development of rabbit skeletal myocytes
and displays different expression patterns in skeletal and cardiac
muscle [3]. Third, GRP94 functions as a stress protein in muscle: its
expression was observed to increase transiently in ﬁbrillating atrial
myocytes [4] and over-expression of GRP94 in stressed cardiomyo-
cytes protected them from cell death [5]. The stress-protecting role is
speciﬁc to GRP94 and is not shared by other endoplasmic reticulum
chaperones like BiP or calreticulin [5].
GRP94 may exert its effects on muscle cells because of two
mutually non-exclusive activities: due to its essential role in the
production of IGF [1,6], on whose activity muscle ﬁbers are dependent
[7–10], or because of its importance for calcium homeostasis [11] in
this excitatory cell type. We were particularly intrigued by thelucose regulated protein; IGF,
emethoxygeldanamycin
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ll rights reserved.possibility that GRP94 is important for muscle growth through its
chaperone activity towards IGF. Over-expression of insulin-like
growth factor-II in mouse embryonic stem cells promotes their
myogenic differentiation [12]. Localized IGF-I transgene expression
enhances muscle hypertrophy [13,14], sustains hypertrophy and
regeneration in senescent skeletal muscle [7], accelerates muscle
regeneration [15] and counters muscle decline in mdx mice [14].
Finally, muscle produces speciﬁc isoforms of IGF-I whose function is
yet unclear [16].
This work shows that GRP94 activity is indeed crucial for myogenic
cell differentiation and that GRP94 is important at an intermediate
phase of myogenesis, because it promotes the production of locally
acting IGF.
2. Materials and methods
2.1. Materials
β estradiol, tunicamycin and thapsigargin were purchased from
Sigma Chemicals (St. Louis, MO). Lipofectamine 2000 transfection
reagent was from Invitrogen (Carlsbad, CA). Recombinant IGF-II was
purchased from GroPep (Adelaide, Australia), recombinant IGF-I was
from R&D systems (Minneapolis, MN). 17-Allylamino-17-demethox-
ygeldanamycin (17AAG) was from InvivoGen (San Diego, CA) and the
XTT viability kit from Roche Applied Science (Indianapolis, IN). DMEM
was from Mediatech, Inc. (Manassess, VA), fetal bovine serum was
Fig. 1. RNAi silencing of GRP94 expression. A. C2C12 cells were stably transfected with
plasmids encoding shRNA 24, 25 or 27, directed against the GRP94 sequence. Detergent
lysates of pools of transfected cells (15 or 50 μg total cell protein for each treatment)
were resolved by SDS–PAGE and immunoblotted with anti-KDEL monoclonal antibody.
A representative experiment is shown. Untreated, non-transfected C2C12 cells. DC,
50 μg of murine dendritic cells proteins, shown for comparison. The positions of GRP94
and BiP are indicated. Quantitation of this and other blots by densitometry is indicated
by the numbers below the blot, which enumerate the immuno-reactivity remaining
relative to untreated cells. B. 10T1/2 cells infected with lentiviruses encoding either
irrelevant RNAi sequence (shCTRL), or anti-GRP94 shRNAs 23–27. Cell lysates were
prepared 7 days after the initial infection. A total of 40 μg of protein was loaded for each
lysate. GRP94 and BiP were detected with the same anti-KDEL monoclonal antibody.
Numbers below the top panel indicate quantitation of the remaining immuno-
reactivity, relative to cells expressing shRNA-CTRL. Tubulin and 14-3-3 were detected
with their respective antibodies and served as loading controls. C. C2C12 and 10T1/
2MD:ER cells stably expressing either shRNA25, an irrelevant shRNA as control
(shCTRL), or untransduced (U) were lysed, and 40 μg of total protein each was resolved
by SDS–PAGE and immunoblotted. The blots were probed with anti-HSP90 antibody,
anti-KDEL or anti-14-3-3 antibodies.
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supplements were from Gibco-Invitrogen (Grand Island, NY).
2.2. Antibodies
Mouse anti-myosin heavy chain (MHC) mAb MF-20 and anti-
troponin T mAb CT-3 were obtained from the Developmental Studies
Hybridoma Bank (at the Univ. of Iowa, Iowa City, IA); mouse anti-
sarcomeric actin from Sigma; mouse mAb anti-p21 from BD
(Pharmingen (CT); rabbit anti-MyoD (C-20), rabbit anti-14-3-3
(C16) and mAb anti-myogenin (F5D) were purchased from Santa
Cruz, Biotechnology, Santa Cruz, CA. mAb anti-desmin (D33) was
from Imgenex (San Diego CA); mAb anti-KDEL was from StressGen
(Vancouver, BC); anti-HSP90 was from BD Transduction Laboratories
(San Jose, CA) and anti-caspase 3 and anti-cleaved caspase 3 (Asp175)
were from Cell Signaling; secondary antibodies conjugated to HRP,
rhodamine or Cy3 were from Jackson ImmunoResearch Laboratories
(West Grove, PA). Biotinylated anti-mouse IGF-II (#BAF792), mono-
clonal anti-IGF-II (MAB792) and polyclonal anti-mouse IGF-II (AF792)
were from R&D Systems (Minneapolis, MN). The anti-GRP94
monoclonal antibody 9G10 (SPA-850) from Stressgen Biotechnologies
(Victoria, BC), recognizes an epitope located in the charged linker of
GRP94 and is a conformation-sensitive antibody [17].
2.3. Cells and differentiation conditions
C2C12 and 10T1/2 were from the ATCC, and 10T1/2 MD:ER cells
were a generous gift from Dr. S. Tapscott (Univ. of Washington, WA).
These cell lines were grown in DMEM in the presence of 10% FBS and
induced to differentiation either by complete withdrawal of serum or
by shifting to medium supplemented with 2% house serum. 10T1/
2MD:ER were induced to differentiate as previously reported [18].
17AAG at concentrations of 10–15 μM was used to inhibit GRP94
activity. Recombinant IGF-II (R&D Systems) at 100–1000 ng/ml, or
conditioned media of differentiated C2C12 cells, were used to
complement differentiation. For proliferation assays using the XTT
formazan colorimetric assay (Roche), cells were grown in 3% serum,
to limit the background of the assay and to enable minimal growth of
the shRNA25-containing cells, which otherwise do not grow.
2.4. Knockdown of GRP94
Seven predicted 21-mer sequences were tested, and three were
effective in knocking down GRP94 expression to at least 50% of wild
type levels. The shRNA clones were from the Mission shRNA library
(Sigma), numbers TRCN 0000071923-27. For plasmid-based RNAi, the
cells were transfected using Lipofectamine 2000 according to the
manufacturer's guidelines. After 48 h they were selected with 2 μg/ml
puromycin and maintained under selection. For viral-based RNAi, the
cells were cultured in 6-well plates and transduced with lentiviral
particles encoding the same shRNA sequences, packaged using the
VeraPower kit (Invitrogen). The MOIs were in the range of 107–108.
After 24 h the cells were selected with puromycin as above.
2.5. Immunostaining
Cells were ﬁxed in 4% paraformaldehyde and permeabilized in
0.25% Triton X-100 for 15 min. Subsequently, the cells were stained
with either anti-myosin heavy chain (MHC) mAb MF-20, or anti-
MyoD, or anti-desmin, followed by secondary antibodies conjugated
to rhodamine or Cy3 (Jackson ImmunoResearch Laboratories, West
Grove, PA). The cells were counterstained to visualize nuclei with
1 ng/ml 4,6-diamidino-2-phenylindole (DAPI) in phosphate-buffered
saline, and thenmounted. Cells were imaged on a Zeiss Axiovert 200M
microscope equipped with a Roper Coolsnap FX-HQ camera. Imageanalysis was performed with the Slidebook v4.0 software (Intelligent
Imaging Innovations, Denver, CO).
2.6. Western blot analysis
Cells were lysed with a 0.5% Nonidet P-40 detergent solution as
described in ref. [6]. Equal amounts of extracted proteins (15–100 μg)
were loaded per lane, separated by SDS–PAGE and transferred to
nitrocellulose membranes. The membranes were incubated in block-
ing buffer (20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 0.1% Tween 20,
and 3% (w/v) nonfat dry milk) and then in 20 mM Tris–HCl (pH 7.4),
150 mM NaCl and 2% (w/v) nonfat dry milk, with the primary and
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(1:1000), anti-desmin (1:500), anti-MyoD (1:500), anti-myogenin
(1:1000), anti-p21 (1:500), anti-myosin heavy chain (1:1000), anti-
troponin T (1:1000), anti-sarcomeric actin (1:2000), anti-KDEL
(1:1000), anti-HSP90 (1:1000), anti-cleaved caspase 3 (1:500), anti-
caspase 3 (1:2000) and anti-14-3-3 (1:2000). Proteins were visual-
ized using the enhanced chemiluminescence kit (Pierce, Rockford, IL).
Images were recorded using an Alpha Inotech imager.2.7. Quantitation of IGF-I and -II; Detection of IGF-I and IGF-II by ELISA
Both factors were detected by ELISA. For IGF-II, plates were coated
with anti-IGF-II (MAb 792, R&D Systems) and incubated with
conditioned media of the indicated cells. The bound IGF-II was
detected with a biotinylated anti-IGF-II antibody (BAF792, R&D
Systems) and developed with streptavidin–HRP (R&D Systems)
according to the manufacturer's recommended procedure. Optical
density units were converted to concentrations of the hormone with aFig. 2. GRP94 silencing results in lack of myogenic differentiation. A. C2C12 cells transfec
constructs were grown in the presence of serum and induced to differentiate by serum dep
heavy chain antibody MF-20 followed by rhodamine-anti-mouse Ig and also counterstained
Note the syncitium of nuclei within a fused myotube in the control cells. Magniﬁcation ba
control shRNA (shCTRL) were grown in the presence of serum for 5 days after viral infectio
indicated times and equal aliquots of cells were harvested for immunoblots on each of da
expression of GRP94. Differentiation was assessed by the induced expression of myosin he
three is shown. C. C2C12 cells transfected either with empty vector or with shRNA25 w
rhodamine-anti-rabbit secondary antibody (red, top panels). DAPI staining was used (blue,
amounts of detergent lysates of the same cultures as in C (15 and 50 μg each sample) were r
differentiation marker. The membrane stained with ponceau S is shown in the bottom pane
proteins were not affected by the RNAi.standard curve generated with recombinant IGF-II (792-MG) (R&D
Systems). Total IGF-I in the media was measured by a commercially
available ELISA kit (MG100, R&D Systems, Minneapolis, MN) as
previously described (Pfeffer et al., 2009). This kit detects total rodent
IGF-I and is not affected by IGF-I binding proteins or IGF-II. It does not
detect equine IGF-I from the horse serum, but can detect endogenous
IGF-I production by murine cells. The assay can detect IGF-I at 30–
2000 pg/ml with an intra-assay precision of 4.3%, and an inter-assay
precision of 5.9%. Data were acquired in duplicate on a microtiter-
plate reader (Dynatech Laboratories, Chantilly, VA) at 450 nm.3. Results
3.1. Speciﬁc silencing of GRP94
To test the mechanism of GRP94 action during muscle develop-
ment, we used two complementary tools: down-regulation of GRP94
expression with RNAi and pharmacological inhibition of its activityted either with empty vector (control), or with shRNA25 (sh25) or shRNA27 (sh27)
letion. Forty-eight hours later, the cells were ﬁxed and stained with the anti-myosin
with DAPI (blue) to visualize nuclei. All cells shown were cultured at the same density.
r, 20 μm. N=4. B. C2C12 cells infected with lentiviruses encoding shRNA25 (sh25) or
n. They were then placed in differentiation medium (2% horse serum) (day 0) for the
ys 0–4. Fifty µm of total protein was loaded on each gel lane. Blots were probed for
avy chain (MHC), sarcomeric actin or troponin T. A representative experiment out of
ere induced to differentiate and 48 h later stained with anti-desmin antibody and
bottom panels) to highlight nuclei. Magniﬁcation bar represents 20 μm. N= 2. D. Equal
esolved by SDS–PAGE and probed with anti-desmin antibody, to show a second muscle
l, not only to serve as a loading control, but also to show that the patterns of total cell
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algorithms, three inhibited GRP94 expression (shRNA24, 25 and 27).
As shown in Fig. 1A, the three shRNA vectors provided a graded series
of knockdown of GRP94 expression in C2C12 cells, with sh25 being
the most effective (typically N90% knockdown), sh24 partially
effective (approximately 60% knockdown), and sh27 intermediate
between them. This rank order of activity held true in a number of
cells tested, both human and murine, muscle and non-muscle cells.
Efﬁcient knockdown via transfection required more than 60 h after
transfection, consistent with the long half-life of GRP94 (N48 h).
Because of the poor transfectability of C2C12, we subsequently
delivered the shRNAs by lentiviral infection, which proved to be a
highly efﬁcient method for knockdown of GRP94 (Fig. 1B). The
speciﬁcity of the shRNA reagents towards GRP94 is demonstrated by
their failure to silence BiP (78 kDa), another ER luminal chaperone.
Both GRP94 and BiP are co-detected in the same blots when using the
anti-KDEL monoclonal antibody (Fig. 1A). Speciﬁcity of knockdown is
also demonstrated by the failure of the anti-GRP94 RNAi to suppress
expression of tubulin, 14.3.3 protein or even the closely related,
cytoplasmic homologue of GRP94, HSP90 (Fig. 1C). ShRNA depletion
of GRP94 in C2C12 or 10T1/2 cells lasted for weeks, enabling us to
follow muscle differentiation with or without GRP94. ShRNA
depletion of GRP94 caused some BiP induction (Fig. 1B), but follow-
up experiments show that this induction does not reﬂect an unfolded
protein response (Eletto et al., in preparation, and see also Fig. 6
below).
3.2. Inhibition of GRP94 in myoblasts reduces muscle differentiation
When GRP94 levels were depleted, the ability of C2C12 cells to
differentiate was inhibited. Fewer cells fused into myotube-like
syncytia (Fig. 2A), fewer cells expressed myosin heavy chain (Fig.
2A) or desmin (Fig. 2C), and the total amount of contractile proteins
produced by the cells was dramatically reduced: induction of myosin
heavy chain, sarcomeric actin, troponin T and desmin expression was
inhibited (Fig. 2B, D). The severity of the differentiation defect
correlated with the extent of knockdown in multiple experiments,
providing good evidence that C2C12 myogenic differentiation is
proportional to the activity of GRP94.
When GRP94 expression was silenced using shRNA24 or shRNA25,
not only expression of muscle proteins, but also production of IGF-II
by differentiating C2C12 cells was strongly inhibited (Fig. 3A).
Similar inhibition of IGF-II secretion was observed in 10T1/2 MD:
ER, another cell line capable of muscle differentiation in culture,Fig. 3. GRP94 silencing leads to inhibition of IGF-II and IGF-I secretion. A. C2C12 cells
expressing shRNA25 (sh25), shRNA24 (sh24) or empty vector (mock) were switched
to differentiation medium for 36 h, in the presence or absence of 10 μM of 17AAG. The
culture media were collected and the concentrations of IGF-II in the media were
determined by ELISA, as described in Materials and methods. All cells were cultured at
the same density. The results represent the mean±SD of three independent
experiments. B. 10T1/2 MD:ER expressing sh25 or control shRNA were grown in
differentiation medium (2% horse serum in the presence of 100 nM of β-estradiol) and
at the indicated time points the levels of IGF-II in the culture media were determined by
ELISA as in A. The results represent the mean±SD of four independent experiments.
The inset shows the blots of shCTRL (C) and sh25 (25) cells, to illustrate the efﬁciency of
silencing. C. IGF-I secretion is also inhibited by GRP94 knockdown. Cumulative
secretion of IGF-I from 10T 1/2 MD:ER cells into the media was measured by ELISA at 1,
3 and 5 days after differentiation. Data are presented asmean±SD for 3measurements.
⁎, Pb0.05 for comparisons to day 1 in the same condition. †, Pb 0.05 for comparisons
between conditions on the same day. One-way ANOVA followed by Tukey's multiple
comparision test. D. IGF-II secretion is stimulated by tunicamycin treatment. IGF-II
secretion was measured in the medium collected from C2C12 cells after 48 h treatment
with 0.25 μg/ml tunicamycin, in either growth medium, serum-free differentiation
medium or 2% horse serum differentiation medium. Note that the low dose of
tunicamycin was chosen to minimize toxicity and enable the measurement of IGF-II
secretion over 48 h. Blank bars, mock treatment. Red bars, tunicamycin treatment.because it expresses estradiol-activatable MyoD [18] (Fig. 3B). The
requirement for GRP94 is not limited to IGF-II, but is shared by the
homologous growth factor IGF-I. When GRP94 expression is
silenced, IGF-I secretion by 10T1/2 MD:ER cells is also inhibited
(Fig. 3C).
The inhibition of both myogenic differentiation and IGF secretion
were conﬁrmed by pharmacological, rather than genetic inhibition of
GRP94 activity. When treated with 17AAG, C2C12 cells did not fuse,
Fig. 4. Complementation of the GRP94 defect by exogenous IGF. A. C2C12 cells that were transfected with shRNA25 (sh25) or with vector alone (control) were induced to
differentiate for 72 hr in low serum, either in the absence or presence of 1 μg/ml of IGF-II (right panel). The cells were stained with anti-myosin heavy chain antibodyMF20 (red) and
counterstained with DAPI (blue). All cells were cultured at the same density. Bar, 20 μm. B. Frequency of myosin heavy chain (MHC)-positive cells. The number of MHC-positive cells
per ﬁeld in images such as shown in A is plotted for each condition. Data represent a total of 41 ﬁelds from three independent experiments, two of which involved complementation
with IGF-II and one with IGF-I. Horizontal lines are the mean values. C. The extent of cell fusion was quantiﬁed by counting the number of nuclei in each MHC-positive cell in the
samples described in A. Only four MHC-positive cells were found in shRNA25-treated cells, and all of them were mononuclear. D. C2C12 cells were induced to differentiate for 24 h.
Then, control cultures received DMSO (0.1% ﬁnal concentration) and experimental cultures received either 15 μM17AAG, or 15 μM17AAG plus 100 nM of IGF-II (right panel), and all
cultures were allowed to differentiate for additional 48 h. The cells were stained as in A. The images represent data from three independent experiments. Bar, 20 μm. E. The number of
myosin heavy chain-positive cells per ﬁeld is plotted for the samples illustrated in panel D. Data represent a total of 40 ﬁelds from two independent experiments. F. Quantitation of
cell fusion by counting the number of nuclei in each MHC-positive cell in the samples described in D.
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signiﬁcant levels of IGF-II (Fig. 3A). While 17AAG affords the
advantage of a rapid assay, it is a less speciﬁc agent, because it
inhibits cytosolic HSP90 just as efﬁciently as GRP94. The combination
of the drug effects and the RNAi phenotype, however, conﬁrms that
GRP94 is essential for myogenesis because of its chaperone activity
towards IGF.
3.3. Complementation with exogenous IGF
Importantly, addition of exogenous IGF to myoblasts with
knocked-down or inhibited GRP94 partially rescued differentiation.
Both the expression of contractile proteins and cell fusion were
restored in the presence of IGF (Fig. 4A–C for RNAi silencing and
Fig. 4D–F for 17AAG inhibition of activity). The rescue shows thatinhibition of GRP94 activity does not cause the cells to be
unresponsive to IGF (and thus receptor expression is likely intact).
Rather, the rescue with IGF is consistent with it being the main
effector through which GRP94 inﬂuences muscle differentiation.
Either recombinant IGF-I or recombinant IGF-II was effective in
restoring myogenesis, consistent with the common receptor, IGF-IR,
and signaling pathway that the two hormones share [19]. C2C12 and
10T1/2MD:ER produce both IGFs, but much more IGF-II than IGF-I
(Fig. 3). It should be noted that the rescue of myogenesis by
exogenous IGFs is incomplete: the median number of MHC-positive
cells observed per ﬁeld increases from near 0 to approximately 4 in
the presence of IGF-II, compared to approximately 7 in untreated
C2C12 cells (Fig. 4B). Similarly, when another parameter is quantiﬁed,
the number of cells fused to yield a myotubes, themedian number is 4
nuclei per myotube in the presence of IGF, as compared to 8 in control
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achieve the optimal concentration of active IGF, or more likely,
because other GRP94 clients that are not complemented are involved
in myogenesis. Nonetheless, the improvement in both parameters
when exogenous IGFs is added to GRP94-depleted cells is impressive.
In addition, a quantitative correlation between the level of IGF-II in
themedium and the quality of muscle differentiation was consistently
observed in multiple silencing experiments (e.g. Figs. 3 and 4). Thus,
we conclude that the major reason for inhibition of muscle
differentiation by silencing GRP94 is the inability of myoblasts to
produce IGF. As we showed previously, GRP94 is an obligatory
chaperone for production of signaling-competent IGF-I and -II and
that it binds to ER forms of the pro-hormones, before they are
processed proteolytically into the mature growth factors [6].
3.4. GRP94 activity is needed for intermediate steps during myogenic
differentiation
We next asked whether the requirement for GRP94 extends
throughout the myogenic program, or whether it is needed at a
particular stage of differentiation. Importantly, silencing GRP94
expression did not prevent the induction of expression of MyoD, the
master transcription factor that initiates the myogenic program; this
was shown by both immunoblots (Fig. 5A) and immunoﬂuorescence
(Fig. 5B).
In contrast to MyoD, the induction of expression of another
muscle-speciﬁc transcription factor, myogenin, was inhibited in
GRP94-deﬁcient C2C12 cells (Fig. 5A). The failure to induce
myogenin is not an exclusive property of C2C12, because myogenin
is also undetectable in muscle differentiation cultures derived from
grp94−/− ES cells [1]. Even in 10T1/2MD:ER cells that over-express
MyoD, the induction of myogenin expression is attenuated by
silencing GRP94 (data not shown). This is consistent with theFig. 5. GRP94 depletion does not affect MyoD, but inhibits myogenin induction. A.
Western blot analysis showing a time course of differentiation of C2C12 cells expressing
either shRNA25 or control shRNA. Blots were probed for expression of GRP94 and for
expression of myogenic transcription factors and cell cycle regulators. 14.3.3 levels
were used as a loading control. A representative experiment out of more than four is
shown. B. C2C12 cells stably expressing sh25 or control shRNA plasmids were placed in
differentiation medium for 24 h then stained with anti-MyoD (red, top panels) and
with DAPI (blue, bottom panels) to highlight nuclei. Note the concentration of MyoD in
nuclei under both conditions. Shown are images representative of three independent
experiments. Bar, 20 μm.known synergism that leads to myogenin promoter activation, which
reﬂects the integrated action of inputs from MyoD and from other
growth factors [20–22]. In fact, the parental 10T1/2 cell line, which
does not express MyoD, cannot differentiate [18] and secrete only
negligible amount of IGF-II (0.94±0.013 ng/ml after 48 h, compared
to the 30 ng/ml level secreted by 10T1/2MD:ER; see Fig. 3B). Since
myogenin acts downstream of MyoD, its dependence on GRP94
activity suggests that the chaperone is not required for the
commitment to myogenesis nor for its initiation, but rather at an
intermediate step in the differentiation program.3.5. Depletion of GRP94 does not cause ER stress and does not change
apoptosis
Silencing of GRP94 in either C2C12 or 10T1/2MD:ER cells leads to
up-regulation of BiP expression (Figs. 1 and 6). This phenomenon is
not the same as typical ER stress response. First, the magnitude of BiP
induction is sub-maximal, as can be seen when compared with BiP
induction using the ER stress inducer thapsigargin (Fig. 6). Second,
many of the targets of ER stress, such as calreticulin and protein
disulﬁde isomerase, are not induced when GRP94 is lost (Eletto et al.,
in preparation). Furthermore, the effect of ER stress on IGF-II secretion
is opposite from the effect of silencing GRP94. As shown in Fig. 3D,
IGF-II secretion is enhanced, not inhibited, by treatment with low
concentrations of tunicamycin, either in growth or differentiation
conditions.
It is known that during myogenic differentiation in culture a
fraction of cells dies by apoptosis induced by ER stress [23,24]. We
uncoupled cell differentiation from apoptosis by using the 10T1/2MD:
ER cells, which can be induced to differentiate with estradiol even in
the presence of serum. When induced with estradiol, these cells
differentiate as shown by up-regulation of MHC expression (Fig. 6A).
Without GRP94, the differentiation is largely inhibited. Under these
conditions, there is no detectable cleavage of caspase 3, the hallmark of
apoptosis (Fig. 6A). If there was signiﬁcant apoptosis, it would have
been easily detected, as shown by activation of caspase 3 when the
same cells are treatedwith the ER stress inducer thapsigargin (Fig. 6A)
[24]. Furthermore, we quantiﬁed nuclear size from DAPI-stained
images such as those shown in Fig. 2, where C2C12 cells differentiate
after the stress of serum withdrawal. There was no increased fraction
of cells with condensed nuclei when sh25-expressing cells were
compared to control cells (Fig. 6B). This is consistent with the
conclusion that depletion of GRP94 does not direct the cells to the
apoptotic pathway.3.6. GRP94 is important for cell cycle control
Myogenesis involves not only commitment to lineage differen-
tiation and expression of muscle-speciﬁc genes, but also
programmed withdrawal from the cell cycle, via down-regulation
of cell cycle activators and up-regulation of cell cycle inhibitors [25].
Indeed, in addition to inhibiting muscle-speciﬁc gene expression,
silencing of GRP94 slows down the cell cycle of myogenic cells.
C2C12 with graded reduced expression exhibit progressively slower
proliferation (Fig. 7A). This is not a property unique to one cell line,
because we observed the reduced proliferation with MCF-7 RD, 293T
and CHO cells, as well as primary chondrocytes (data with MCF-7
shown in Fig. 7B, representative of the other cells). Silencing of GRP94
reproducibly led to higher expression of the cell cycle inhibitor p21
even in growth medium, before the induction of differentiation (Fig.
5A). Consistent with the levels of p21, cyclin D1 expression was lower
in C2C12 whose GRP94 expression was silenced (data not shown).
These data correlate well with the observed reduced proliferation
rate.
Fig. 6. GRP94 depletion affects differentiation but does not increase apoptosis. A. 10T1/2 MD:ER cells expressing either sh25 or shCTRL were grown in the presence of 15% FCS
and allowed to differentiate by provision of β estradiol. The cells were harvested at the indicated times and 40 μg of total protein each was resolved by SDS–PAGE and analyzed
by western blotting with the indicated antibodies. To control for detection of cleaved caspase 3 the cells were treated with 1 μM thapsigargin for 24 h, a dose known to induce
ER stress and cause apoptosis. Dying cells that detached from the plates and expressed active caspase 3 were easily detected in the thapsigargin-treated cultures, but were not
detectable in the other conditions, including the sh25-expressing cells. Note that the induction of BiP in GRP94-depleted cells is sub-maximal in comparison to the induction
following thapsigargin treatment. B. C2C12 cells expressing either shRNA25 or shRNA-CTRL were allowed to differentiate as described in Fig. 2 and stained with DAPI. Nuclear
size was determined by quantifying their circumference using the analysis module of SlideBook, and the distribution of nuclei values in each sample was plotted. Bar, the
mean nuclear.
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This work demonstrates that myogenic differentiation in culture
requires the activity of the ER stress protein GRP94 and provides a
molecular explanation for this requirement. We show that GRP94 is
needed primarily through its effect on the production of IGFs, growth
factors that are very important for muscle development as well as for
maintenance of muscle mass [26,27]. As we recently showed using
another experimental system, GRP94 acts as a chaperone towards
IGF-II, and without its activity pro-IGF-II is not processed to the
mature, active hormone, and is consequently not secreted [6]. It has
long been known that differentiation of myoblasts into contractile
myotubes involves autocrine secretion of IGF, both IGF-I and IGF-II,
and we show here that GRP94 is needed for this essential step in
myogenesis. We further show that the requirement for GRP94 is not
for initiation of myogenesis, but rather during a downstream step in
the differentiation program, after the induction of MyoD and before
the increase of myogenin.
The stage(s) of myogenesis that require GRP94 coincides with the
timing of the requirement for IGF, as shown before [28,29]. IGF
signaling integrates environmental cues with the intrinsic genetic
program controlled by MyoD- and MEF2-family transcription factors,
creating an autocrine network where MyoD enhances later differen-
tiation steps by induction of local action of a growth factor [21]. On the
other hand, growth factor signaling enhances MyoD expression by
affecting transcriptional co-regulators that are essential co-factors for
MyoD, thus establishing an ampliﬁcation cascade for sustaining early
events in muscle differentiation [29].Although a priori the failure of myogenesis in the absence of
GRP94 can be attributed to multiple client proteins whose production
may be needed for terminal differentiation, the activity of GRP94
towards IGF plays a dominant role in this process, because supplying
the hormone exogenously complements myoblast fusion and termi-
nal differentiation even in cells lacking GRP94. Therefore, even if
other proteins also rely on GRP94 activity, their role in differentiation
is not essential. For example, GRP94 was shown to be required for
proper surface expression of some, but not all integrins [30] and
integrins are known to be required for fusion-competence of myo-
blasts [31]. Nonetheless, GRP94-depleted cells can still fuse when
provided only with IGF. Therefore, there is apparently sufﬁcient
compensatory activity provided by GRP94-independent integrins.
This conclusion is in line with the data on integrin-deﬁcient myo-
blasts reviewed in ref. [31].
Another line of evidence pointing to the major role of the GRP94-
IGF axis is the stage of myogenesis that requires GRP94 activity. In
GRP94-depletedmyogenic cells there was a normal level of MyoD, but
expression of myogenin, desmin, myosin heavy chain, troponin T, and
sarcomeric actin was undetected. The timing of the requirement for
IGF is also after MyoD induction and before myogenin expression
[28,29]. Readouts of IGF actions are shown to be critical for activation
of myogenic speciﬁc promoters, protein synthesis, apoptosis, regen-
eration and hypertrophy in muscle [8,29,32,33]. Since GRP94-
depleted muscle cells are not able to produce IGF, MyoD-initiated
differentiation in these cells fails to proceed to the terminal stages.
Thus, completion of myogenic differentiation requires the GRP94-IGF
axis.
Fig. 7. GRP94 depletion inhibits cell proliferation. A. C2C12 cells expressing either sh25
or control RNAi were grown in the presence of 3% FCS (see Materials and methods) for
different time points. Proliferation rate of the each cell line wasmeasured by XTT assays
according to the manufacturer's instructions. A representative experiment is shown. B.
MCF-7 cells stably expressing sh25 or treated with 10 μM 17AAG were grown for the
indicated time points and their proliferation was measured by XTT assays as above.
DMSO treatment (the solvent control for 17AAG) did not differ from the vector control
shown. N= 3.
340 O. Ostrovsky et al. / Biochimica et Biophysica Acta 1803 (2010) 333–341Our data are complementary to the previous observations by
Gorza et al. that increased expression of GRP94 serves as a protective
mechanism against muscle stress, such as calcium overload in
cardiomyocytes [4,5,34]. We suggest that increased GRP94 expression
is needed to promote the production of local IGF by the stressed
myocytes, enabling them to better cope with the stress. Interestingly,
Frasson et al. recently reported that early in myocyte differentiation, a
fraction of GRP94 is phosphorylated and then exported from the
endoplasmic reticulum to the Golgi complex [35]. Phosphorylation of
GRP94 had also been reported in cardiac myocytes [36]. The
functional relation of this phosphorylated pool of GRP94 molecules
to the IGF-dependent promotion of muscle differentiation is currently
unknown and experiments are now in progress to pursue this
intriguing relationship. Our data also add to the published work that
argues that the unfolded protein response has a positive inﬂuence on
myogenesis. For example, Nakanishi et al. showed that pre-treatment
of C2C12 cells with tunicamycin or thapsigargin actually promotes
differentiation of the cells that survived the apoptotic fate [37]. We
ﬁnd that low-dose tunicamycin treatment not only induces some
unfolded protein response, but also promotes IGF-II secretion, even in
growth conditions without induction of the complete differentiation
program. Nonetheless, the effects of the unfolded protein response aredistinct from the effects of depletion of GRP94, even if the two
processes share the induction of BiP expression.
Although we focus on IGF in this work, our data do not exclude
other activities or targets of GRP94 that may inﬂuence muscle
differentiation. For example, GRP94 is known to be a high capacity
calcium-binding protein [38] and this activity is necessary for
calcium homeostasis [11]. It is quite likely that without the
calcium-binding capacity of GRP94, sarcoplasmic reticulum differen-
tiation is compromised. Non-IGF mediated effects are also suggested
by the incomplete complementation of the phenotype with IGF.
Furthermore, our data show that GRP94 activity is important also for
cell cycle control even before differentiation commences, and
withdrawal from the cell cycle is known to be required for myogenic
differentiation [39,40]. Even though GRP94-deﬁcient cells have
higher level of p21 under growth conditions, they fail to execute
the differentiation program. At present we do not have a molecular
explanation for the intersection of GRP94 with cell cycle regulators.
Additional mechanisms are also worth exploring; GRP94 is known to
be important for proper expression of some integrins [30] and this
may be important in the fusion-competence of myoblasts.
The evidence reported in this article indicates that GRP94 is
essential for muscle formation primarily because its chaperone
activity is required for the production of IGF. We propose that not
only IGF-II, but also IGF-IA and other related isoforms are dependent
on GRP94. Therefore, a method to tune the activity of GRP94 would
affect a number of target proteins simultaneously and would be
advantageous over modulation of each client protein separately in
order to improve muscle physiology.Acknowledgements
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